Search - tctmd.com

Displaying 21 - 31 of 31

Sort: Relevancy | Date

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

News Conference News ACC 2017

FDA Warns of Risk of Major Adverse Cardiac Events With Absorb BVS

Michael O'Riordan

March 18, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

So, You Want to Implant BVS? Essential Techinques for Simple and Complex Lesions

Presentation SIF 2017

So, You Want to Implant BVS? Essential Techniques for Simple and Complex Lesions

Presenter: David G. Rizik

March 10, 2017

TCTMD’s Top 10 Most Popular Stories for February 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2017

March 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

December 29, 2016

News Opinion Editor's Corner

TCTMD 年十大热门新闻、博客和焦点

December 29, 2016

News Daily News

Absorb BVS Meets Performance Goal in Diabetic Patients, but Is It Enough to Justify a Broader Label?

Yael L. Maxwell

December 23, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

September 01, 2016

News Features

The Bioresorbable Stent Story So Far: What Promise? What Price?

Michael O'Riordan

August 17, 2016

News Daily News

Now You See It: FDA Approves Absorb Bioresorbable Scaffold

Michael O'Riordan

July 05, 2016

Are Regulatory Approval Clinical Trials Too Complex and Too Costly for New Devices and New Indications? EXCEL and BVS Experience.

Presentation TCT 2013

Are Regulatory Approval Clinical Trials Too Complex and Too Costly for New Devices and New Indications? EXCEL and BVS Experience.

Presenter: Charles Simonton

October 30, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.